A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology)
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
The CRC Digest